Demystifying Bacteriocins of Human Microbiota by Genome Guided Prospects: An Impetus to Rekindle the Antimicrobial Research

The human microbiome is a reservoir of potential bacteriocins that can counteract multidrug resistant bacterial pathogens. Unlike antibiotics, bacteriocins selectively inhibit a spectrum of competent bacteria and are said to safeguard gut commensals, reducing the chance of dysbiosis. Bacteriocinogen...

Full description

Saved in:

Bibliographic Details
Published in:	Current protein & peptide science Vol. 23; no. 12; p. 811
Main Authors:	Suryaletha, Karthika, Savithri, Akhila Velappan, Nayar, Seema A, Asokan, Sijo, Rajeswary, Divya, Thomas, Sabu
Format:	Journal Article
Language:	English
Published:	United Arab Emirates 01-01-2022
Subjects:	Anti-Bacterial Agents - pharmacology Bacteria - genetics Bacteriocins - genetics Bacteriocins - pharmacology Humans Microbiota bacteriocin gene clusters (BGCs) human microbiome LAB bacteriocinogenic probiotics antimicrobial peptides Bacteriocin
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The human microbiome is a reservoir of potential bacteriocins that can counteract multidrug resistant bacterial pathogens. Unlike antibiotics, bacteriocins selectively inhibit a spectrum of competent bacteria and are said to safeguard gut commensals, reducing the chance of dysbiosis. Bacteriocinogenic probiotics or bacteriocins of human origin will be more pertinent in human physiological conditions for therapeutic applications to act against invading pathogens. Recent advancement in the omics approach enables the mining of diverse and novel bacteriocins by identifying biosynthetic gene clusters from the human microbial genome, pangenome or shotgun metagenome, which is a breakthrough in the discovery line of novel bacteriocins. This review summarizes the most recent trends and therapeutic potential of bacteriocins of human microbial origin, the advancement in the in silico algorithms and databases in the discovery of novel bacteriocin, and how to bridge the gap between the discovery of bacteriocin genes from big datasets and their in vitro production. Besides, the later part of the review discussed the various impediments in their clinical applications and possible solution to bring them into the frontline therapeutics to control infections, thereby meeting the challenges of global antimicrobial resistance.
ISSN:	1875-5550
DOI:	10.2174/1389203724666221019111515